000 01397 a2200409 4500
005 20250517232033.0
264 0 _c20181003
008 201810s 0 0 eng d
022 _a1879-0631
024 7 _a10.1016/j.lfs.2018.07.053
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aLeng, Bin
245 0 0 _aAstragaloside IV improves vascular endothelial dysfunction by inhibiting the TLR4/NF-κB signaling pathway.
_h[electronic resource]
260 _bLife sciences
_cSep 2018
300 _a111-121 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAnimals
650 0 4 _aCytokines
_xmetabolism
650 0 4 _aDiabetes Mellitus, Experimental
_xcomplications
650 0 4 _aDiabetic Angiopathies
_xetiology
650 0 4 _aEndothelium, Vascular
_xdrug effects
650 0 4 _aMale
650 0 4 _aNF-kappa B
_xantagonists & inhibitors
650 0 4 _aRats
650 0 4 _aRats, Sprague-Dawley
650 0 4 _aSaponins
_xpharmacology
650 0 4 _aSignal Transduction
650 0 4 _aToll-Like Receptor 4
_xantagonists & inhibitors
650 0 4 _aTriterpenes
_xpharmacology
700 1 _aTang, Futian
700 1 _aLu, Meili
700 1 _aZhang, Zhen
700 1 _aWang, Hongxin
700 1 _aZhang, Yingjie
773 0 _tLife sciences
_gvol. 209
_gp. 111-121
856 4 0 _uhttps://doi.org/10.1016/j.lfs.2018.07.053
_zAvailable from publisher's website
999 _c28703813
_d28703813